• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

accelerated approval

sketching charcoal filling in filling out fill in fill out sketch
Pharma

BMS is augmenting Zenbexus' efficacy profile in multiple myeloma

BMS has put up the progression-free survival numbers on its recently-approved Zenbexus, more than doubling the score over a control cocktail of DVd.
Fraiser Kansteiner Oct 8, 2026 2:25pm
Karyopharm

Karyopharm reports Xpovio miss, FDA filing in separate cancers

Jul 31, 2026 10:00am
hearing audio waves

Regeneron ushers in new era with inaugural gene therapy approval

Apr 23, 2026 3:22pm
FDA

More transparency, evidence needed for accelerated nods: ICER

Apr 17, 2026 11:22am
opening door to brick wall
Favicon Fierce Biotech

Senate hearing takes aim at FDA's rare disease review process

Feb 26, 2026 3:50pm
U-turn pivot about-face

Atara, Pierre Fabre receive 2nd US rejection for Ebvallo

Jan 12, 2026 11:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings